A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer.

Abstract

Standard chemotherapeutic drugs, when modified by the frequency and dose of administration, can target angiogenesis. This approach is referred to as antiangiogenic chemotherapy, low-dose chemotherapy, or metronomic chemotherapy. This study evaluated the feasibility of 6 months of metronomic chemotherapy, its toxicity and tolerability, surrogate markers of… (More)

Topics

Cite this paper

@article{Kieran2005AFT, title={A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer.}, author={Mark W Kieran and Christopher D. Turner and Joshua B. Rubin and Susan N. Chi and Mary Ann Zimmerman and Christine A. Chordas and Giannoula Lakka Klement and Andrea M Laforme and Amanda L Gordon and A. L. Thomas and Donna Neuberg and Timothy D. Browder and Judah M Folkman}, journal={Journal of pediatric hematology/oncology}, year={2005}, volume={27 11}, pages={573-81} }